Market Overview

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

Share:

Newly manufactured plasmids will be applied in clinical trials
evaluating Oncoprex™ in combination with targeted therapies and
immunotherapies

Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy
company developing a new approach to treating cancer based upon a novel
proprietary technology platform, has signed an agreement with Aldevron,
a leading contract manufacturing organization, to supply TUSC2 (Tumor
Suppressor Candidate2) plasmid DNA for use in Genprex's clinical
development program evaluating its immunogene therapy Oncoprex™ for the
treatment of non-small cell lung cancer.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180927005155/en/

"Plasmid DNA plays an important role in the delivery of gene therapies
into target cells," said Rodney Varner, Chairman and Chief Executive
Officer of Genprex. "Aldevron is a leading plasmid manufacturer that
offers world-class laboratory and manufacturing programs. Through this
agreement, we have established a GMP-validated supply of plasmid DNA
vectors for our expanding clinical program evaluating the utility of
Oncoprex in combination with some of the most promising new therapies
for cancer."

"Aldevron is honored to partner with Genprex in the development of
Oncoprex," said Michael Chambers, CEO of Aldevron. "This collaboration
furthers our goal to provide high-quality plasmid DNA and other
biologics to leading companies such as Genprex that are creating
treatments that could have a significant impact on human health."

About Aldevron

Aldevron serves the biotechnology industry with custom production of
nucleic acids, proteins, and antibodies. Thousands of clients use
Aldevron-produced plasmids, RNA and gene editing enzymes for projects
ranging from discovery research to clinical trials to commercial
applications. These products are critical raw materials and key
components in commercially available drugs and medical devices. Aldevron
specializes in GMP manufacturing and is known for inventing the
GMP-SourceTM quality system. Company headquarters are in
Fargo, N.D., with additional facilities in Madison, Wis., and Freiburg,
Germany.

About Genprex™, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new
approach to treating cancer, based upon a novel proprietary technology
platform, including Genprex's initial product candidate, Oncoprex™
immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's
platform technologies are designed to administer cancer fighting genes
by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells
where they express proteins that are missing or found in low quantities.
Oncoprex™ has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed cell
death, in cancer cells, and modulates the immune response against cancer
cells. Oncoprex™ has also been shown to block mechanisms that create
drug resistance.

For more information, please visit www.genprex.com or www.facebook.com/genprexinc.

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effect of TUSC2 on cancer, the products and
services we expect to receive from Aldevron and the effect of those
products and services on the development of Oncoprex™. Risks that
contribute to the uncertain nature of the forward-looking statements
include the presence and level of TUSC2's effect on cancer, Aldevron's
ability to provide products and services to us and our ability to
utilize Aldevron's products and services, the ability of Aldevron's
products and services to influence the development of Oncoprex™, as well
as the timing and success of our clinical trials and planned clinical
trials of TUSC2 and Oncoprex™ and our other potential product candidates
and the timing and success of obtaining FDA approval of Oncoprex™ and
our other potential product candidates. These and other risks and
uncertainties are described more fully under the caption "Risk Factors"
and elsewhere in our filings and reports with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on
which they were made.

View Comments and Join the Discussion!